Summary

  • Zymeworks describes three sources for the proposed $929 million Theravance cash consideration: a $350 million non-recourse note from OMERS Life Sciences, about $360 million of expected Theravance net cash and $219 million of Zymeworks cash. The sum is exact, but it is a forecast closing bridge rather than a final balance sheet.
  • The OMERS note is expected to bear 8.25% annual interest and receive quarterly payments equal to the lesser of 75% of YUPELRI net profit or the outstanding balance. Non-recourse protects the rest of Zymeworks; it does not remove the creditor’s priority over the pledged drug cash flow.
  • Theravance holders are to receive $17 a share plus a non-tradable ampreloxetine contingent value right. Any payment is unsecured and depends on events and transactions that Zymeworks is not obliged to pursue; the buyer can withhold consent in its sole discretion and owes holders no fiduciary duty.
  • A forecast $100 million TRELEGY milestone in the first quarter of 2027 could reduce Zymeworks’s effective $219 million investment toward $119 million if its conditions are met. That is a possible later receipt, not closing finance and not cash already collected.

Three numbers finance Zymeworks’s proposed purchase of Theravance Biopharma. One of them belongs to the buyer.

The companies put the cash consideration at approximately $929 million. Zymeworks says $350 million is to come from a non-recourse note supplied by OMERS Life Sciences. It expects about $360 million of net cash to remain inside Theravance at closing. Zymeworks would supply the remaining $219 million from its own resources. The equation is satisfying because it closes without a residual: 350 plus 360 plus 219 is 929.

It is also a poor description of the economics. A dollar of target cash, a dollar borrowed against YUPELRI and a dollar taken from Zymeworks’s treasury are interchangeable at the payment agent. They are not interchangeable after the merger. Target cash passes under the buyer’s control. The note gives a creditor an interest-bearing claim against a ring-fenced revenue asset. Zymeworks cash is equity capital at risk. The holders surrendering Theravance shares receive $17 in cash and a contingent contract whose value is decided on the other side of closing.

The proposed acquisition therefore has two prices. The first is the amount written on the cheque. The second is the order in which the acquired assets will serve their new claimants.

The target supplies the largest funding block

Theravance’s contribution is not a semantic trick. Zymeworks’s transaction announcement explicitly identifies the target’s expected net cash of approximately $360 million as one of the sources for the remaining purchase price. On the latest reported balance sheet before the announcement, Theravance had $219.8 million of cash and $167.9 million of short-term marketable securities. Its June quarterly report summarized cash, equivalents and marketable securities at $387.7 million, excluding restricted cash, with no long-term debt.

Those two figures should not be collapsed. The $387.7 million is an observed 30 June balance. The $360 million is management’s expected net cash at a future closing, after whatever operating receipts, spending, transaction costs and permitted movements occur in between. A closing statement will have to turn the estimate into a fact.

Nor does target cash make the acquisition free. Zymeworks acquires that cash because it is buying the company that owns it. The shareholders’ $17 cash consideration buys both the operating and financial assets that remain in the perimeter. Saying Theravance “pays for itself” would erase the value of what holders are surrendering. The precise point is narrower and more useful: 38.8% of the announced cheque is expected to be funded by liquidity already held in the target.

That changes the buyer’s exposure. Zymeworks reported $322.5 million of cash, equivalents and marketable securities at 30 June. Its own quarterly filing says operations used $77.7 million in the first half and share repurchases absorbed $128.1 million. A $929 million all-treasury purchase would not resemble the disclosed balance sheet. The target cash and creditor financing let Zymeworks acquire a larger asset perimeter while contributing an amount below its reported liquid resources.

That is financing efficiency, not economic proof. The target balance can move before closing. Integration and restructuring consume cash. Acquired liabilities travel with acquired assets. Purchase accounting may identify intangibles and goodwill, but it does not create liquidity. The first post-closing receipt should therefore show the final target cash delivered, the final cash Zymeworks contributed and any adjustments to the $929 million figure.

OMERS is paid from the asset it helps buy

The second funding block changes the order of cash. The definitive proxy recounts a $350 million OMERS financing structured as a royalty bond. The stated collateral includes YUPELRI profit-share payments and the related intellectual property, licences and other assets, along with the assets of specified guarantors. It bears 8.25% annual interest. Quarterly payments equal the lesser of 75% of YUPELRI net profit or the outstanding balance.

“Non-recourse” is the feature Zymeworks stresses. The note is not supposed to reach the rest of its business. That boundary matters to its other shareholders and creditors. But a ring fence has two faces. The creditor cannot claim everything; the owner cannot freely deploy everything inside the fence. Under Zymeworks’s description, 75% of the YUPELRI profit-share cash flow is contractually assigned to service the note.

YUPELRI is not an owned sales force producing a simple royalty cheque. Viatris leads US commercialisation, and Theravance holds a 35% share of US profit and loss. The target recognised $20.7 million under that collaboration in the June quarter, 11% more than a year earlier. YUPELRI net sales grew 7%, while customer demand grew 10%. Full-year 2025 US net sales were $266.6 million.

Each noun matters. Net sales belong to the product’s commercial account. Theravance’s collaboration revenue reflects its share under the agreement. “Net profit” is the measure named for servicing the proposed note. None is automatically equal to the others. A lender presentation can turn an annualised run rate into a financing narrative; debt service requires cash calculated under the executed contract.

At 8.25%, $350 million implies $28.9 million of simple annual interest before principal reduction, fees or timing effects. That multiplication is an illustration, not a repayment forecast. Actual payments are constrained by the defined quarterly sweep and will depend on the profit stream. Stronger YUPELRI performance could retire the obligation more quickly but divert more near-term cash to OMERS. Weaker performance would preserve less cash for everyone and could leave the note outstanding longer. Non-recourse reallocates the downside boundary; it does not abolish downside.

The financing also changes what “adds YUPELRI cash flow” means. Zymeworks gains the asset, but most of the relevant cash is initially spoken for. The value retained by the buyer depends on growth, the definitions in the note, the duration of the sweep and the residual after the creditor is served. Those are observable variables. “Balance-sheet flexibility” is management’s description of the structure, not a substitute for them.

The buyer keeps control with the smallest closing block

Zymeworks’s disclosed $219 million contribution is 23.6% of the stated consideration. It is the smallest of the three funding blocks, yet it purchases the controlling position.

The buyer receives Theravance as a wholly owned subsidiary if the merger closes. It obtains the residual YUPELRI economics, additional potential YUPELRI milestones and ex-US royalties, VIBATIV royalties, preclinical research assets and the corporate structure in which Theravance’s tax attributes sit. Zymeworks highlighted approximately $2.5 billion of Irish tax attributes for potential future use.

That face amount is not cash and should not be added to the consideration. Tax losses and other attributes create value only if law, ownership restrictions, structure and taxable income allow them to offset future tax. A deferred-tax accounting conclusion is another step again. The number identifies optional capacity, not a collectible receivable.

The same discipline applies to TRELEGY. Zymeworks expects Theravance to receive a $100 million Royalty Pharma milestone in the first quarter of 2027, assuming the conditions are met. If that cash arrives after a completed merger, subtracting it from the buyer’s $219 million closing contribution gives $119 million. That is the basis for management’s statement that its effective net investment could be reduced by roughly half.

But the subtraction crosses time and probability. The $219 million is planned closing funding. The $100 million is a forecast later milestone. Until Royalty Pharma’s conditions are satisfied and the cash is received, it cannot finance the closing, repay OMERS or reimburse Zymeworks. Readers should be able to see those ledgers separately rather than encountering a single “net investment” number that makes the milestone look inevitable.

Zymeworks’s capital model provides context. Earlier in 2026, a subsidiary borrowed $250 million from Royalty Pharma against a ring-fenced Ziihera royalty interest. That is a separate transaction, not part of the Theravance funding. It nevertheless shows a repeatable preference: monetise or borrow against partner-generated product cash flows while preserving recourse boundaries around the parent. Theravance extends the model from an existing royalty stream to an acquisition in which an operating product pays a creditor that helped finance its transfer.

Former holders get a claim without the steering wheel

Theravance shareholders are not selling every possibility for $17. The merger announcement also promises one contingent value right for each eligible share. The CVR tracks ampreloxetine, the drug candidate whose Phase 3 CYPRESS study missed its primary endpoint in February.

The potential payments have three channels. Holders may receive 80% of net proceeds actually received from an ampreloxetine licence, divestiture or other monetisation transaction executed during the ten years after closing. They may share a $50 million milestone if a first commercial sale occurs in one of six named countries within the licence window. They may also receive 10% of net sales, country by country, from the first commercial sale through the later of its tenth anniversary, patent expiry or loss of exclusivity.

Those terms preserve upside, but not control. The proxy says any transaction capable of generating a payment needs Zymeworks’s prior written consent. The buyer may grant or withhold that consent in its sole discretion. It has no obligation to seek, negotiate, pursue or complete a transaction, no defined diligence or performance duty, and no fiduciary duty to consider the interests of CVR holders. Its tax position may enter the consent decision.

For one year after closing, a Theravance designee can seek an ampreloxetine deal. Zymeworks says no additional resources are expected from it. That arrangement supplies a search party, not an independent decision-maker. Consent remains with the buyer.

The legal rank is equally plain. The CVR is not stock. It carries no vote, dividend or ownership interest, and it generally cannot be traded. For any amount that might become payable, a holder has no greater rights against Zymeworks than a general unsecured creditor. OMERS, by contrast, is expected to hold collateral and a defined sweep from YUPELRI. The two future claims emerge from the same acquisition but occupy opposite positions: one has priority over a proven product cash flow; the other waits unsecured on an uncertain asset under the buyer’s discretion.

That distinction is the transaction’s most revealing piece of market design. Shareholders receive certainty for the mature cash-producing asset and an instrument for the failed-trial optionality. Zymeworks retains 20% of any qualifying licence economics and all operating authority. It can rationally consider its own tax attributes, portfolio choices and capital needs. The CVR contract explicitly refuses to require those choices to maximise the former holders’ outcome.

A broad process does not make the claims equivalent

Theravance’s latest supplemental filing gives unusually granular counts. After a December 2025 board meeting, Lazard contacted 60 potential counterparties. Twenty signed confidentiality agreements, 15 received a management presentation and 12 conducted limited diligence. The board considered a whole-company sale, sales of individual assets and a structure that would convert YUPELRI into a passive royalty and distribute cash.

That history supports the claim that outreach was broad. It does not show 60 bids. It does not identify 12 financed offers. One alternative bidder proposed a different mix of cash and a YUPELRI-linked contingent right; Viatris declined to bid for the whole company. Zymeworks’s own proposal moved from $16.60 a share with no CVR on 15 June to the signed $17 plus the ampreloxetine CVR.

The board concluded that a whole-company transaction was more tax-efficient and accretive to holders, and its advisers delivered a fairness opinion under the assumptions described in the proxy. Those are relevant process receipts. They do not collapse the post-closing priorities into one common interest.

The supplement followed three shareholder complaints and 13 demand letters alleging disclosure deficiencies. Theravance and the other defendants denied the allegations, called them meritless and said the added disclosure was voluntary to reduce cost and delay. The counts improve the public record; they are not an admission that the process was defective, and the litigation is not evidence of wrongdoing.

The cleanest evaluation therefore avoids both slogans. It is too simple to call the deal a giveaway because the target supplies cash. It is equally simple to call the financing non-dilutive and stop there. The proposed sale converts one balance sheet into four different positions: cash consideration for former holders, collateralised debt for OMERS, control and residual economics for Zymeworks, and an unsecured contingent claim for ampreloxetine.

Sources